Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hangzhou Alltest Biotech CoSHSE:688606 +1.04%53 PB Ratio is 0.90 as of Jul. 29, 2026, which is 35% below its 10-year median of 1.39. GuruFocus rates SHSE:688606 with a GF Score™ of 53/100 and a GF Value™ of ¥85.89 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Hangzhou Alltest Biotech Co ranks better than 81.7% on this metric.
Hangzhou Alltest Biotech Co Ltd stock PB Ratio (=0.86) is close to 10-year low of 0.84.
The historical rank and industry rank for Hangzhou Alltest Biotech Co's PB Ratio or its related term are showing as below:
SHSE:688606'
s PB Ratio Range Over the Past 10 Years
Min: 0.84 Med: 1.39 Max: 6.26
Current: 0.9
During the past 10 years, Hangzhou Alltest Biotech Co's highest PB Ratio was 6.26. The lowest was 0.84. And the median was 1.39.
SHSE:688606's PB Ratio is ranked better than 81.7% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.04
vs SHSE:688606: 0.90
During the past 12 months, Hangzhou Alltest Biotech Co's average Book Value Per Share Growth Rate was -1.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -1.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 18.90% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Hangzhou Alltest Biotech Co was 125.20% per year. The lowest was -1.60% per year. And the median was 89.20% per year.
Back to Basics: PB Ratio
Hangzhou Alltest Biotech Co (SHSE:688606) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Hangzhou Alltest Biotech Co PB Ratio Related Terms
Hangzhou Alltest Biotech Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688606 vs ISRG, BDX, MDLN: PB Ratio Comparison
For the Medical Instruments & Supplies subindustry, Hangzhou Alltest Biotech Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Alltest Biotech Co PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hangzhou Alltest Biotech Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Hangzhou Alltest Biotech Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Hangzhou Alltest Biotech Co (SHSE:688606) has a PB Ratio of 0.90 as of Jul. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Hangzhou Alltest Biotech Co and its competitors. This is 35% below median its historical median of 1.39. Over the past decade, Hangzhou Alltest Biotech Co's PB Ratio has ranged from 0.84 to 6.26. According to the industry distribution chart, Hangzhou Alltest Biotech Co ranks #144 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 18.3%.
Is Hangzhou Alltest Biotech Co's PB Ratio too high?
Hangzhou Alltest Biotech Co's current PB Ratio of 0.90 is 35% below median its 10-year median of 1.39. Over the past 10 years, this metric has ranged from a low of 0.84 to a high of 6.26. The Medical Devices & Instruments industry median PB Ratio is 2.04. Hangzhou Alltest Biotech Co's value of 0.90 is 55.9% below this industry median. Based on the distribution chart, Hangzhou Alltest Biotech Co ranks #144 out of 787 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Hangzhou Alltest Biotech Co has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Alltest Biotech Co's PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Hangzhou Alltest Biotech Co ranks #144 out of 787 companies for PB Ratio. This places Hangzhou Alltest Biotech Co in the top 18% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.04. Hangzhou Alltest Biotech Co's value of 0.90 is 55.9% below this benchmark. Historically, Hangzhou Alltest Biotech Co's own PB Ratio has ranged from 0.84 to 6.26 over the past decade. While the company's 10-year median is 1.39 vs. the industry median of 2.04, Hangzhou Alltest Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.04, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou Alltest Biotech Co's current PB Ratio of 0.90 is 55.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Hangzhou Alltest Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Alltest Biotech Co's current PB Ratio is 0.90, which is 35% below median its own 10-year median of 1.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Alltest Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Alltest Biotech Co (SHSE:688606) is currently considered Possible Value Trap. The stock's GF Value™ is ¥85.89, compared to a current price of ¥43.92 — trading 48.9% below its estimated fair value. The current PB Ratio is 0.90, which is 35% below median its 10-year median of 1.39 and 55.9% below the Medical Devices & Instruments industry median of 2.04. Hangzhou Alltest Biotech Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Hangzhou Alltest Biotech Co (SHSE:688606), the current PB Ratio is 0.90 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Alltest Biotech Co (SHSE:688606) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Alltest Biotech Co stock appears to be undervalued.
The current stock price of ¥43.92 is trading 48.9% below its estimated GF Value™ of ¥85.89.
GuruFocus considers Hangzhou Alltest Biotech Co to be Possible Value Trap.
Key valuation signals for SHSE:688606:
PB Ratio: 0.90 (35% below median its 10-year median of 1.39)
GF Value™: ¥85.89 vs. price of ¥43.92 (48.9% below fair value)
Industry Position: 55.9% below the Medical Devices & Instruments median (#144 of 787)
No single metric tells the full story. See the SHSE:688606 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688606 has been successfully added to your 
